Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure.

ABSTRACT:

Objectives

This study sought to identify the role of annexin A1 (AnxA1) as a congestion marker in acute heart failure (AHF) and to identify its putative role in predicting clinical outcomes.

Background

AnxA1 is a protein that inhibits inflammation following ischemia-reperfusion injury in cardiorenal tissues. Because AHF is a state of tissue hypoperfusion, we hypothesized that plasma AnxA1 levels are altered in AHF.

Methods

In the Renal Optimization Strategies Evaluation (ROSE) trial, patients hospitalized for AHF with kidney injury were randomized to receive dopamine, nesiritide, or placebo for 72 hours in addition to diuresis. In a subanalysis, plasma AnxA1 levels were measured at baseline and at 72 hours in 275 patients. Participants were divided into 3 tertiles bas

SUBMITTER: Adel FW 

PROVIDER: S-EPMC7484139 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature